Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE GERVASI

Allopathic & Osteopathic Physicians Urology

NPI
1265400592
CMS profile
328763
Location
MIDDLEBURG HEIGHTS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$152,151.65

224 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE GERVASI

NPI 1265400592 · CMS profile ID 328763

Allopathic & Osteopathic Physicians / Urology

MIDDLEBURG HEIGHTS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265400592?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265400592?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265400592?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LAWRENCE GERVASI, NPI 1265400592, CMS profile ID 328763, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1265400592?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

224 matching records · $152,151.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 224 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 224.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sumitomo Pharma America, Inc. $335.9508/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148855239 CMS
Sumitomo Pharma America, Inc. $335.9508/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148855241 CMS
ABC Home Medical Supply, Inc. $22.6607/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144936792 CMS
Blue Earth Diagnostics Limited $37.6107/31/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1147791006 CMS
Verity Pharmaceuticals Inc. $16.9007/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080604920 CMS
Sumitomo Pharma America, Inc. $18.7507/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148855237 CMS
Sumitomo Pharma America, Inc. $448.1307/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148855233 CMS
Sumitomo Pharma America, Inc. $448.1307/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148855235 CMS
Blue Earth Diagnostics Limited $107.9507/11/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1147790995 CMS
Dendreon Pharmaceuticals LLC $29.9207/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149316132 CMS
Janssen Biotech, Inc. $15.8007/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524590 CMS
Astellas Pharma US Inc $452.9207/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139381604 CMS
Astellas Pharma US Inc $141.8107/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139381612 CMS
Astellas Pharma US Inc $203.5807/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139381614 CMS
Astellas Pharma US Inc $5,600.0007/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139381640 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.4807/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086191696 CMS
Janssen Biotech, Inc. $41.1407/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524293 CMS
Janssen Biotech, Inc. $3,575.0007/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524711 CMS
PFIZER INC. $22.0706/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131698177 CMS
Janssen Biotech, Inc. $84.8206/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524530 CMS
Janssen Biotech, Inc. $3,575.0006/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524695 CMS
Janssen Biotech, Inc. $5.5006/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524554 CMS
PROGENICS PHARMACEUTICALS, INC. $20.5806/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128510609 CMS
Janssen Biotech, Inc. $74.9906/20/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524538 CMS
Bayer Healthcare Pharmaceuticals Inc. $1,657.1306/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086079308 CMS
Astellas Pharma US Inc $4,800.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387568 CMS
Astellas Pharma US Inc $57.9206/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387588 CMS
Bayer Healthcare Pharmaceuticals Inc. $5,292.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086124848 CMS
Tolmar, Inc. $26.8406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138703763 CMS
ABC Home Medical Supply, Inc. $22.6606/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144936790 CMS
Astellas Pharma US Inc $581.6906/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387566 CMS
Astellas Pharma US Inc $68.2806/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387570 CMS
Astellas Pharma US Inc $4,800.0006/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387572 CMS
Astellas Pharma US Inc $439.4506/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387574 CMS
Janssen Biotech, Inc. $15.4306/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524393 CMS
Astellas Pharma US Inc $17.4506/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139358867 CMS
Verity Pharmaceuticals Inc. $18.3706/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080604916 CMS
ConvaTec Inc. $34.3906/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151374164 CMS
PROGENICS PHARMACEUTICALS, INC. $16.5306/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128510641 CMS
Blue Earth Diagnostics Limited $18.5305/28/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1147790969 CMS
Janssen Biotech, Inc. $645.2505/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524475 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.4005/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086131096 CMS
Astellas Pharma US Inc $15.4805/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387590 CMS
Telix Pharmaceuticals $24.1305/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081982814 CMS
Dendreon Pharmaceuticals LLC $27.8505/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149316130 CMS
PFIZER INC. $20.6805/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131578703 CMS
Janssen Biotech, Inc. $5.5005/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078524690 CMS
Tolmar, Inc. $20.5405/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138703761 CMS
IMMUNITYBIO, INC. $14.4805/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125508148 CMS
Astellas Pharma US Inc $689.5305/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387576 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $198,015.38 281
PY2020 $91,147.75 149
PY2021 $104,760.68 177
PY2022 $182,488.44 241
PY2023 $177,656.74 249
PY2024 $152,151.65 224
PY2025 $145,937.60 210

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $97,228.40 28
PY2024 Principal investigator $380,223.92 43
PY2023 Principal investigator $426,904.31 37
PY2022 Principal investigator $637,507.29 81
PY2021 Principal investigator $582,019.29 97
PY2020 Principal investigator $765,957.29 159
PY2019 Principal investigator $791,586.46 139

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $27,750.00 12/23/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175427662
Principal investigator 1 Janssen Research & Development, LLC $787.50 11/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175427565
Principal investigator 1 Janssen Research & Development, LLC $26,000.00 10/30/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175427732
Principal investigator 1 Janssen Research & Development, LLC $7,311.20 06/12/2025 Non-covered Recipient Entity
Clnc Rsrch Solutions, Llc
A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1175300954
Principal investigator 1 MEDIVATION LLC. $697.45 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829382
Principal investigator 1 MEDIVATION LLC. $1,245.40 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829470
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829491
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829499
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829734
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829788
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829827
Principal investigator 1 MEDIVATION LLC. $1,406.60 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829832
Principal investigator 1 MEDIVATION LLC. $1,573.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829837
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829845
Principal investigator 1 MEDIVATION LLC. $1,406.60 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829850
Principal investigator 1 MEDIVATION LLC. $1,406.60 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829894
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829964
Principal investigator 1 MEDIVATION LLC. $1,406.60 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829972
Principal investigator 1 MEDIVATION LLC. $312.00 05/21/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228829978
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,500.00 04/04/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185537307
Principal investigator 1 MEDIVATION LLC. $1,070.00 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SOLUTIONS LLC
PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228831590
Principal investigator 1 Sumitomo Pharma America, Inc. $6,500.00 03/05/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH INC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630235
Principal investigator 1 Sumitomo Pharma America, Inc. $5,000.00 03/05/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH INC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630239
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 03/05/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH INC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630242
Principal investigator 1 MEDIVATION LLC. $312.00 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SOLUTIONS LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228832073
Principal investigator 1 MEDIVATION LLC. $697.45 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SOLUTIONS LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228832250
Principal investigator 1 MEDIVATION LLC. $312.00 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SOLUTIONS LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228832255
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,850.00 02/05/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185537305